Four Swiss-based companies will received state funding to develop a range of new drugs to treat coronavirus, which are expected to be available by the end of 2022.
This content was published on
1 minute
swissinfo.ch/dos
Português
pt
Governo suíço financia quatro novos medicamentos contra a Covid
The contracts were signed in the context of the Federal Funding Programme for Covid-19 Medicines, run by the Federal Office for Public Health (FOPH) and the Swiss Innovation Agency Innosuisse, the government said on MondayExternal link.
The total value of the four deals is CHF27 million ($29.2 million).
The projects aim to treat a range of the symptoms caused by a Covid-19 infection and to mitigate the length and severity of illness.
Two of the drugs are monoclonal antibody treatments: one for the neuropsychiatric symptoms in sufferers of long Covid, and the other for use on patients at risk of a severe course of Covid-19. A third project is developing an oral pulmonary vasodilator which makers hope will prevent respiratory failure and reduce the need for artificial ventilation.
A final project is an antiviral and anti-inflammatory to treat “all severities of Covid-19”.
Switzerland will enjoy “certain benefits” in return for its investment, the government stated. This includes having a first option on purchases of the drugs.
The government’s medical procurement capabilities to tackle the coronavirus pandemic come under the remit of the Covid-19 law, approved for a second time by voters in a nationwide referendum two weeks ago.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Have you heard something about Swiss diplomacy that you’d like us to fact check?
Not all information circulating about Switzerland’s foreign relations is accurate or well understood. Tell us what you'd like us to fact check or clarify.
Credit Suisse Nazi ties ‘ran deeper than thought’: media report
This content was published on
Credit Suisse is alleged to have withheld details of its historic links with World War II-era Nazi clients, says the Wall Street Journal.
Swiss man faces life imprisonment after Australia drugs arrest
This content was published on
Swiss man, 21, accused of attempting to smuggle 25 kilograms of cocaine with a street value of CHF4.5 million into Australia.
Swiss insurer Helvetia says 500 jobs affected by cost-cutting
This content was published on
Some 500 jobs, including 200 to 250 in Switzerland, are affected by the new operational efficiency measures recently announced by insurer Helvetia.
This content was published on
Significantly fewer new cars were sold in Switzerland in 2024 than the previous year as demand for electric cars and plug-in hybrids declined.
Three Swiss brands among world’s 100 most valuable firms
This content was published on
Three Swiss firms made it into the 2024 top 100 most valuable companies in the world, despite Roche, Nestlé and Novartis falling down the rankings.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
It’s not all about age: why Covid hits some people harder than others
This content was published on
New insights: two studies involving Swiss scientists suggest genes and blood sugar levels play a crucial role in the course of Covid-19.
This content was published on
Should we be afraid of virus variants? Will vaccines be effective against new virus forms? Genomic epidemiologist Emma Hodcroft offers some insight.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.